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Objectives. We sought to determine the prevalence, intensity
and evolving changes of myocardial damage detected by myocar-
dial uptake of antimyosin antibodies in patients with alcohol-
induced dilated cardiomyopathy, alcohol addicts attending a
detoxification unit and healthy subjects with short-term alcohol
consumption.
Background. Evidence of alcohol-induced myocardial damage
may be provided by myocardial uptake of indium-111–labeled
monoclonal antimyosin antibodies. The spectrum of such damage
in patients who are heavy drinkers (>100 g for >10 years), with
or without cardiomyopathy, and the impact of short-term alcohol
ingestion on antimyosin antibody uptake have not been ade-
quately explored.
Methods. One hundred twenty antimyosin studies were per-
formed in 56 patients with dilated cardiomyopathy (group I), 15
alcohol addicts attending a detoxification unit (group II) and 6
volunteers for short-term alcohol ingestion (group III). Estima-
tion of antibody uptake was calculated through a heart/lung ratio
(HLR) (normal <1.55).
Results. The 56 patients in group I (54 men, 2 women; mean
[6SD] age 46 6 11 years) had consumed 123 6 60 g/day of
alcohol for 21 6 9 years, for a cumulative intake of 914 6 478 kg.
Mean duration of symptoms was 46 6 49 months. Mean left
ventricular end-diastolic diameter was 71 6 10 mm, and mean
ejection fraction was 28 6 12%. No differences in New York Heart
Association functional class, ventricular size or ejection fraction
were noted between 28 active and 28 past consumers, except for
the prevalence and intensity of antibody uptake (75% vs. 32%, p <
0.001) and HLR (1.75 6 0.26 vs. 1.49 6 0.17, p 5 0.0001). In 19
patients in the active group restudied after alcohol withdrawal,
antibody uptake decreased (from 1.76 6 0.17 to 1.55 6 0.19, p <
0.001), and ejection fraction improved (from 30 6 12% to 43 6
16%, (p < 0.001). No changes occurred in the 15 past consumers
restudied. The 15 male patients in group II (mean age 36 6 4
years) had consumed 156 6 59 g/day for 17 6 5 years, for a
cumulative alcohol intake of 978 6 537 kg, an amount similar to
that in patients in group I, but antimyosin antibody uptake was
detected in only 3 (20%) of 15 patients. None of six group III
subjects developed antibody uptake after short-term ethanol
ingestion. Despite the small sample size, the power to detect
clinically relevant differences in most variables that did not reach
statistical significance was amply sufficient.
Conclusions. In alcohol-induced dilated cardiomyopathy, alco-
hol withdrawal is associated with the reduction or disappearance of
myocardial damage and improvement of function. The difference in
prevalence of antimyosin antibody uptake in patients with and
without cardiac disease who consume similar amounts of alcohol
suggests the presence of those with different myocardial susceptibil-
ities to alcohol. Short-term ethanol ingestion in healthy subjects does
not induce detectable uptake of antimyosin antibodies.
(J Am Coll Cardiol 1997;29:160–7)
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Assessment of the effects of short- and long-term consumption
of alcohol on the human myocardium has been based on
changes in cardiac function, both after short-term alcohol
consumption in normal subjects (1–8), and after alcohol
withdrawal in long-term drinkers (9–19). An alternative means
to evaluate the impact of alcohol consumption on the myocar-
dium is by noninvasive detection of myocardial damage with
indium-111 (111In)–labeled monoclonal antimyosin antibodies.
Binding of these antibodies to the myocardium only occurs
when the sarcolemma is disrupted and the intracellular myosin
is exposed, signaling the presence of irreversible myocyte
damage (20–24). We and other investigators (25–40) have
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used antimyosin antibodies to assess the presence, intensity or
evolving changes of myocardial damage in conditions where
such damage is diffuse, as in myocarditis, rejection or drug-
induced myocardial disease. In some of these instances, anti-
myosin antibodies provide diagnostic information not obtain-
able from other, more conventional means (41,42).
The present work focuses on three aspects of possible
alcohol-induced myocardial disease: 1) the prevalence and
evolution of myocardial damage in patients with alcohol-
induced dilated cardiomyopathy according to the activity of
their drinking habit; 2) the prevalence of damage in subjects
addicted to alcohol attending an alcohol detoxification unit;
and 3) the impact of short-term alcohol consumption on
antimyosin uptake in healthy subjects. These studies describe
the spectrum of alcohol-induced myocardial disease beyond
analysis of ventricular function.
Methods
Patients. A total of 120 antimyosin antibody studies were
performed in three groups of patients.
Group I. From 1986 to 1995, systematic evaluation of
alcohol consumption was undertaken in every patient with
dilated cardiomyopathy referred to our institution for possible
heart transplantation. Of the 205 patients referred, 56 (27%)
had an alcohol consumption $100 g/day for .10 years, and
they were deemed to have alcohol-induced dilated cardiomy-
opathy (43). None had been referred from a psychiatric unit.
Coronary angiography was normal or showed nonsignificant
coronary disease in 33 patients but was not performed in the
remaining 23,,50 years old and without a history of chest pain
or risk factors for coronary disease. At the time of the study,
patients were taking diuretic drugs, nitrates, hydralazine,
angiotensin-converting enzyme inhibitors or digitalis. All pa-
tients received anticoagulant therapy.
Patients who admitted to alcohol intake up to the time of
antimyosin study or within the previous 3 months were classi-
fied as active consumers; all others were considered past
consumers. Preliminary results of 29 of the 56 patients included
in group I have been reported (31).
Group II. A series of 15 consecutive patients referred to a
specialized alcohol detoxification unit who fulfilled the diag-
nostic criteria for alcoholism were studied. Included were
those patients with a history of active alcohol consumption
within the month before the antimyosin study. Patients with a
history of chest pain, hypertension, diabetes, drug addition or
associated conditions were not referred. To include the pres-
ence of coronary artery disease, patients .50 years old were
not included.
Group III. Six young healthy subjects were studied with
antimyosin before and after short-term ethanol exposure. No
history of alcohol consumption, hypertension, diabetes, renal
or thyroid disease, hypercholesterolemia, chest pain or regular
athletic activity was reported, and none were taking drugs.
Mild to moderate exercise was allowed the week before the
study. Baseline electrocardiographic (ECG), Doppler-
echocardiographic and antimyosin studies were performed
before and after 3 days of alcohol consumption. The study was
approved by the hospital’s Ethics Committee for Clinical
Investigation, and written informed consent was obtained from
the study participants.
Electrocardiographic, echocardiographic and Doppler
measurements. Groups I and II. Left ventricular function was
assessed by echocardiography by independent observers
(G.P.L., F.C.) with no knowledge of the clinical data and
results of antimyosin scans. Left ventricular end-diastolic di-
ameter was measured by two-dimensional-guided M-mode
echocardiography, and left ventricular ejection fraction was
calculated using Simpson’s method (44).
Group III. After baseline ECG, Doppler-echocardiographic
and antimyosin studies, the six volunteers were admitted to a
pharmacology unit for 3 consecutive days. In the fasting state,
they were given 1.2 g/kg of ethanol (whisky diluted in juice to
a total of 400 ml) in 30 min (total amount 3.6 g/kg). Blood
alcoholemia was determined before ingestion and at 30, 60, 90,
120 and 150 min thereafter. Sixty minutes after alcohol inges-
tion, serum levels of creatine kinase, lactate dehydrogenase
and aldolase were determined. On the third day, and 90 min
after the start of alcohol administration, ECG and Doppler-
echocardiographic studies were performed, and antimyosin
antibodies were injected.
Electrocardiographic variables included PR, QRS and
heart rate-corrected QT intervals. Doppler-echocardiographic
measurements were made by a Vigmed CFM-700 cardiac
ultrasound imaging unit equipped with a 3.5-MHz trans-
ducer. Left ventricular measurements were made by two-
dimensional-guided M-mode echocardiography taken from the
two-dimensional echocardiogram using a parasternal ap-
proach. Left ventricular diameters and ejection fraction were
calculated as previously reported (44). Continuous Doppler
studies of flow velocities across the aortic and pulmonary
valves were performed either from the apical or precordial
approaches, depending on where the optimal flow profile was
obtained. Pulsed Doppler studies across the mitral and tricus-
pid valves were performed with the sample volume placed at
the level of the annulus from an apical four-chamber view
(45–47). Adequate alignment between blood flow and the
ultrasound beam was obtained with the aid of color flow
Doppler. Detection of possible regurgitant flows was per-
formed by means of either pulsed wave Doppler or color flow
mapping (48,49). Doppler flow variables included were maxi-
mal aortic and pulmonary velocities and aortic and pulmonary
acceleration times. Diastolic Doppler mitral flow velocities and
time intervals analyzed were the ratio of early peak flow
velocity (peak E) to atrial peak flow velocity (peak A), mitral
deceleration time of early peak flow velocity (ms) and isovolu-
metric relaxation period (ms between the closure of the aortic
valve and the early peak flow velocity) (45). These Doppler
diastolic indexes have previously been shown (47) to have
satisfactory reproducibility. The tricuspid deceleration time
(ms) was obtained in postrespiratory apnea from the Doppler
tricuspid inflow velocity.
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Monoclonal antimyosin antibody studies. A dose of 0.5 mg
of R11D10-Fab-diethylenetriamine pentaacetic monoclonal
antimyosin antibody (Centocor) was labeled with 2.0 mCi of
111In-chloride and administered intravenously. Imaging was
undertaken at 48 h after the injection in the anterior view with
the use of a large field of view camera with a high resolution
medium-energy collimator and 20% window centered on 247-
and 173-keV peaks. A minimum of 500,000 counts between 5
and 10 min was collected, and the images were stored for
analysis.
Interpretation of antimyosin scans was performed by calcu-
lation of a heart/lung ratio (HLR), as previously reported (26).
This method provides a semiquantitative estimation of the
relative cardiac antibody uptake with a very low intraobserver
and interobserver variability; a cutoff of HLR ratio of 1.55 was
used to differentiate normal from abnormal antimyosin studies
(26).
Statistical analysis. Chi-square analysis was used to test
differences between active and past alcohol consumption
groups for categoric variables and an unpaired t test for
continuous variables. A paired t test was used to compare
changes in antimyosin uptake and echocardiographic variables
in the same patients. In group III, the Wilcoxon test was used
to assess variations in antimyosin uptake and Doppler-
echocardiographic variables before and after alcohol consump-
tion. The relation between pairs of continuous variables was
examined with correlation analysis. Data are expressed as
mean value 6 SD; p # 0.05 was considered statistically
significant.
Results
Group I. Fifty-six patients (54 men, and 2 women; 25 to 73
years old, mean age 46 6 11) had consumed 123 6 60 g/day of
alcohol for 21 6 9 years, for a cumulative intake of 914 6
478 kg. The interval from presentation to antimyosin study
ranged from 1 to 256 months (mean 46 6 49). Thirty-six
patients (64%) had a history of chronic heart disease (.1
year), and 20 had acute (,3 months, 9 patients) or subacute
disease (3 to 12 months, 11 patients). Twenty-seven patients
were in New York Heart Association functional class II, and 29
were in functional class III or IV. Mean left ventricular
diastolic diameter was 71 6 10 mm and mean ejection fraction
28 6 12%. The follow-up period ranged from 1 to 94 months
(mean 48 6 30).
Group I included 28 active and 28 past alcohol consumers,
and both groups were similar in age (47 6 11 vs. 45 6 11
years), duration of symptoms (54 6 59 vs. 39 6 37 months),
presentation of disease (.1 year, 61% vs. 68%), functional
class (2.76 0.8 vs. 2.86 0.8), daily alcohol intake (1176 43 vs.
1296 75 g), duration of alcohol consumption (226 10 vs. 206
8 years), cumulative amount of alcohol (927 6 483 vs. 901 6
480 kg), left ventricular end-diastolic diameter (70 6 10 vs.
72 6 10 mm) and ejection fraction (28 6 11% vs. 29 6 12%).
However active and past consumers differed in prevalence of
antimyosin antibody uptake (21 [75%] of 28 vs. 9 [32%] of 28,
p, 0.001) and intensity of uptake (HLR 1.756 0.26 vs. 1.496
0.17, p , 0.0001).
An inverse correlation was noted between the interval
between cessation of alcohol consumption and HLR (r 5
20.37, p , 0.01). Cumulative alcohol consumption did not
correlate with left ventricular size, ejection fraction or HLR.
Follow-up and repeat studies (Fig. 1). A total of 34 patients
were restudied. Nineteen of 28 active consumers underwent
repeat study 9 6 4 months after cessation of alcohol consump-
tion. The remaining nine patients died of heart failure (four
patients), died suddenly (three patients), underwent heart
transplantation (one patient) or could not be restudied (one
patient). A reduction in HLR from 1.76 6 0.17 to 1.55 6 0.19
(p , 0.001) was associated with improvement in left ventricu-
lar ejection fraction (from 30 6 12% to 43 6 16%, p , 0.001)
but no change in diastolic diameter (from 71 6 10 to 67 6
13 mm).
Repeat studies were performed in 15 of 28 past alcohol
consumers 19 6 11 months after the initial study. The remain-
ing 13 patients underwent heart transplantation (4 patients),
died of congestive heart failure (2 patients) or could not be
restudied (7 patients). No significant changes were detected in
HLR (from 1.55 6 0.16 to 1.54 6 0.19), left ventricular
diastolic diameter (from 71 6 8 to 70 6 13 mm) or ejection
fraction (from 31 6 13% to 35 6 16%).
At the end of the follow-up period, 29 (85%) of 34 patients
restudied had residual left ventricular dilation (.55 mm), 11 of
34 had an improved ejection fraction (to .50%), and 23 of 34
had impaired ventricular contraction of varying degrees. Myo-
cardial uptake of antimyosin antibodies was absent in 17
patients but persisted in 17 (10 former active, 7 past consum-
ers).
Group II. Group II included 15 men (mean age 36 6 4
years, range 29 to 45 y), who had consumed 156 6 59 g (range
80 to 276 g) of alcohol for 17 6 5 years (range 10 to 30),
totaling a cumulative alcohol intake of 9786 537 kg (range 432
to 2,678). The echocardiogram disclosed a normal-sized, prop-
erly contracting heart in all patients with a mean left ventric-
ular diastolic diameter of 46 6 6 mm (range 40 to 55) and an
ejection fraction 77 6 5% (range 73% to 84%).
The HLR ranged from 1.27 to 1.70 (mean 1.446 0.17), and
only 3 (20%) of 15 patients had myocardial uptake of antimyo-
sin antibodies. Repeat studies performed in these three pa-
tients with positive scan results showed disappearance of
antibodies uptake in two who refrained from alcohol and
persistence in the remaining patient, who did not stop drink-
ing.
When the clinical, echocardiographic and isotopic features
of groups I and II were compared, it was noted that age was
higher in group I, whereas the daily dose of alcohol was higher
in group II. Years of consumption and calculated cumulative
alcohol intake were similar in both groups, whereas the
prevalence of antimyosin uptake was higher in group I (p ,
0.01) (Table 1).
Group III (Table 2). Group III included six male volun-
teers (24 6 5 years, range 20 to 32; mean weight 72 [6 14] kg,
range 50 to 91). Approximately 60 min after short-term
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administration of alcohol, every subject developed dizziness
compatible with mild to moderate acute alcohol intoxication,
but none developed nausea or vomiting. A manifest diuresis
(988 6 369 ml) followed within 120 min of drinking, but there
was no evidence of cardiac rhythm disturbances. On the third
day, the blood ethanol concentration before ingestion was
1.8 6 0.5 mmol/liter. After 60 to 109 g (mean 86 6 17) of
alcohol, blood ethanol concentrations at 30, 60, 90, 120 and
150 min were 18 6 10, 27 6 7, 26 6 4, 23 6 5 and 22 6
6 mmol/liter, respectively.
Creatine kinase, lactate dehydrogenase and aldolase
blood concentrations were normal before alcohol adminis-
tration, and no significant changes were detected after
exposure. No electrocardiographic or Doppler echocardio-
graphic changes were noted, except for an increase in
maximal pulmonary velocity (p , 0.05). Antimyosin uptake
was not detected after ethanol consumption, and the HLR
Figure 1. Repeat antimyosin and echocardiographic studies in pa-
tients with alcohol-induced dilated cardiomyopathy. Left, Patients with
active alcohol consumption before and after cessation of drinking.
Right, Patients with alcoholic dilated cardiomyopathy and past con-
sumption. In the active group, decrease or disappearance of myocar-
dial uptake of antimyosin antibodies is accompanied by improvement
of ejection fraction. In past consumers, no statistically significant
modifications are noted in repeat antimyosin or echocardiographic
studies. DD 5 echocardiographic end-diastolic left ventricular diam-
eter; EF 5 echocardiographic left ventricular ejection fraction;
HLR 5 heart/lung ratio of antimyosin antibody uptake.
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was similar before (1.37 6 0.1) and after (1.36 6 0.1)
ethanol consumption (p 5 0.28).
Discussion
The present study strongly suggests that alcohol consump-
tion is the main cause of myocardial damage and dysfunc-
tion in some subjects. In long-term alcoholic addicts who
present with dilated cardiomyopathy, the prevalence and
intensity of antimyosin uptake were higher in active than in
past alcohol consumers, and cessation of alcohol consump-
tion in the former led to a reduction or disappearance of anti-
body uptake.
The basic mechanism of myocardial uptake of antimyosin
Table 1. Clinical Features, Alcohol Consumption and Antimyosin Uptake in Alcoholic Patients, With







Age (yr) 47 6 11 36 6 4 , 0.001
Alcohol/day (g) 117 6 43 156 6 59 , 0.02
Consumption (yr) 22 6 10 17 6 5 0.07
Cumulative amount (kg) 927 6 483 978 6 537 0.75
LVEDD (mm) 70 6 10 46 6 6 , 0.001
LVEF (%) 28 6 11 77 6 5 , 0.001
Prevalence of antimyosin uptake 21/28 (75%) 3/15 (20%) , 0.01
HLR 1.74 6 0.26 1.44 6 0.17 , 0.001
*Patients in group I who actively consumed alcohol at time of evaluation with antimyosin antibodies. †Group II
patients. Data presented are mean value 6 SD or number (%) of patients. HLR 5 heart/lung ratio; LVEDD 5 left
ventricular end-diastolic diameter; LVEF 5 left ventricular ejection fraction.


































Basal 65 50 69 242 1.2 1.0 80 110 1.33 60 6.5 3.0 1.40
After ethanol 71 47 74 233 1.2 1.1 90 120 1.33 70 4.0 2.8 1.40
Subject 2
Basal 66 44 77 171 1.0 1.0 90 150 2.00 40 4.9 3.0 1.35
After ethanol 78 42 76 158 1.1 1.1 90 150 1.25 50 5.0 3.9 1.35
Subject 3
Basal 68 50 82 226 1.1 0.9 105 140 1.40 65 4.3 3.0 1.20
After ethanol 88 48 80 241 1.1 1.0 110 100 1.75 55 4.3 3.2 1.20
Subject 4
Basal 80 52 58 241 1.0 0.8 95 140 1.25 60 2.3 2.5 1.35
After ethanol 75 52 67 258 1.2 0.9 110 130 1.50 70 2.8 2.7 1.30
Subject 5
Basal 65 54 70 192 1.3 0.9 90 130 1.40 60 4.6 2.2 1.44
After ethanol 58 50 66 211 1.2 0.9 90 90 1.75 50 3.9 2.9 1.40
Subject 6
Basal 57 50 76 274 1.0 0.8 100 140 2.25 85 6.7 3.1 1.50
After ethanol 68 51 80 266 1.4 1.2 100 150 2.00 50 4.5 3.3 1.52
Mean
Basal 65 50 72 224 1.1 0.9 93 135 1.60 61 4.9 2.8 1.37
After ethanol 71 48 73 228 1.2 1.0* 98 123 1.59 57 4.0 3.1 1.36
SD
Basal 10 3 8 37 0.1 0.8 8 13 0.41 14 1.6 0.3 0.10
After ethanol 5 4 6 39 0.1 0.1 9 25 0.28 10 0.7 0.4 0.10
*p , 0.05, basal versus after ethanol intake. AAT 5 aortic acceleration time; E/A ratio 5 peak E wave velocity/peak A wave velocity ratio; IVRT 5 isovolumetric
relaxation time; LV 5 left ventricular; MAV 5 maximal aortic velocity; MDR 5 mitral deceleration time; MPV 5 maximal pulmonary velocity; PAT 5 pulmonary
acceleration time; TDR 5 tricuspid deceleration rate; other abbreviations as in Table 1.
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antibodies is related to the penetration of the Fab fragments of
this antibody through the cellular membrane (22). In alcohol-
induced myocardial disease, this penetration could result from
damage to sarcolemmal proteins directly produced by alcohol
(14,50) or indirectly by fatty acid ethyl esters, an end-product
of the myocardial metabolism of alcohol experimentally shown
to damage myocardial cells (51–56).
After cessation of alcohol exposure, reduction or disappear-
ance of antimyosin uptake was associated with significant
improvement, or even normalization, of left ventricular func-
tion, thus establishing a link between damage and function in
dilated cardiomyopathy of alcoholic origin. Despite functional
improvement, several sequelae were observed after cessation
of alcohol: 1) left ventricular dilation, which reflects the
difficulty of ventricular remodeling in advanced stages of
disease; 2) low ejection fraction, probably due to the myocar-
dial mass lost during active alcohol consumption; and 3)
myocardial damage, detected by antimyosin. The significance
of the latter finding is not clear: It could be due to undetected
lack of compliance to alcohol abstention, inclusion of patients
with idiopathic dilated cardiomyopathy (who show a high
prevalence of antimyosin uptake [29]) or myocardial damage
due to end-stage heart failure (57).
Correlation between damage and function before and after
cessation of alcohol consumption. Figure 2 describes con-
structs that express the possible relations between myocardial
damage and status of ventricular function both before and
after cessation of alcohol consumption.
These constructs suggest the existence of four elements: 1)
the normal myocardium; 2) the recent and irreversibly dam-
aged myocardium (detected by antimyosin); 3) the reversibly
impaired myocardium (not detected by antimyosin); and 4) the
myocardial mass lost as a result of alcohol-induced injury.
The previous considerations suggest that in the evaluation
of patients with alcoholic dilated cardiomyopathy, uptake of
antimyosin antibodies may provide a marker of important
alcohol exposure but is not useful to estimate the extent of
myocardial damage or to predict the presence or magnitude of
functional ventricular recovery after cessation of alcohol.
Antimyosin uptake in patients with cardiomyopathy and
patients undergoing detoxification. Twenty-one of the 28 pa-
tients with dilated cardiomyopathy and active alcohol con-
sumption had myocardial damage, but such damage was
observed in only 20% of patients undergoing alcohol detoxifi-
cation exposed to similar quantities of alcohol, years of con-
sumption and total cumulative alcohol intake (Table 1). Be-
cause the design of the present study was not aimed at forming
comparable groups, the cohort studied (groups I and II) can be
related only with caution: Differences were detected in age
(selection bias in group II resulted in patients with cardiomy-
opathy who were 10 years older than those without cardiomy-
opathy), daily doses of alcohol (higher in group II) and in left
ventricular morphology and function. Whether these variables,
or others not considered or suspected, could account for the
different prevalence of myocardial damage found in these two
groups is unknown. Age is an important determinant of clinical
presentation in alcoholic heart disease (12), but whether given
more years of habitual alcohol consumption, the younger
group II patients would have developed myocardial damage
detectable by antimyosin, is uncertain. The status of left ventric-
ular function is a second consideration. The crucial question is
whether heart failure itself can be associated with antimyosin
uptake. In this respect, studies performed in patients with end-
stage heart failure not due to cardiomyopathy (i.e., coronary
disease) reveal antibody uptake in only 8% of patients (29).
The explanation for the differences in antimyosin uptake in
groups I and II may be related to the fact that heavy alcohol
consumption does not induce myocardial damage in all sub-
Figure 2. Possible constructs of the relation between normally
functioning myocardium, myocardial damage detected by
monoclonal antimyosin antibody uptake and undamaged but
functionally impaired myocardium during and after cessation
of alcohol intake. A to D, Four possible situations during
long-term active alcohol consumption. A, Low susceptibility
(or resistance) to alcohol (e.g., 12 patients in group II), where
ventricular function is normal and no myocardial damage is
detected. B, Ventricular function is normal, but damage is
detected and could represent early evidence of or limited
ethanol-induced myocardial damage (e.g., three patients in
group II). C and D, Two possible constructs in patients with
alcoholic dilated cardiomyopathy and antimyosin uptake that
are clinically indistinguishable at the time of consumption.
Only cessation of alcohol consumption will reveal the evolu-
tion to pattern E (recovery of function and absent damage), F
(no antimyosin uptake but variable degrees of dysfunction due
to previous myocardial mass loss) or G (persistent antimyosin
uptake in addition to decreased left ventricular function).
Arrows 5 possible evolution after cessation of alcohol con-
sumption.
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jects. Genetic susceptibility could be responsible, as previously
shown (58) in other forms of alcohol-induced disease.
Effects of short-term alcohol intake in healthy subjects.
Repeated short-term alcohol exposure has been deemed by
several investigators to be the basis of permanent cardiac
dysfunction. However, conflicting results of short-term alcohol
consumption on ventricular function in normal subjects have
been reported. Some suggest that transient left ventricular
impairment occurs, whereas others show the inability of short-
term alcohol ingestion to elicit functional changes (1–8).
The present work addresses the effect of short-term alcohol
ingestion on antimyosin antibody uptake. Our results show that
1.2 g/kg per day given in 30 min for 3 consecutive days, a daily
dose similar to that previously reported (2,5,6), is not associ-
ated with the development of antimyosin uptake or functional
left ventricular changes. Lack of impact of ethanol exposure on
antimyosin uptake could be due to 1) the inability of antimyo-
sin to detect very small degrees of myocardial damage; 2)
transient alcohol exposure incapable of inducing such damage
(50,52,59); or 3) study subjects who were not susceptible to the
effects of alcohol.
Limitations of the study. In group I, the end-stage situa-
tion of patients included precludes drawing conclusions appli-
cable to earlier phases of the disease. Comparison between
groups I and II was not aimed at testing the hypothesis of
different susceptibilities to alcohol, which can only be ap-
proached by an appropriate hypothesis-driven study. The
power achieved with the current sample size amply covers the
need for detecting clinically relevant differences in those
variables that did not reach statistical significance in the
analyses (0.75 for 450 g of cumulative-year alcohol consump-
tion, 0.98 for 10 years of consumption (Table I) and 0.98 for
0.20 units of HLR, 0.99 for 15-mm left ventricular end-diastolic
diameter and 0.95 for 15% units of left ventricular ejection
fraction, considering in all cases the largest standard deviation
(Fig. 1, right).
Conclusions. In alcoholic dilated cardiomyopathy, alcohol
withdrawal is associated with the reduction and disappearance
of myocardial damage and improvement of function. A differ-
ent prevalence of antimyosin antibody uptake in patient with
and without cardiac disease who drink similar amounts of
alcohol suggest the presence of subjects with different myocar-
dial susceptibilities to alcohol. Short-term ethanol ingestion in
healthy subjects does not induce detectable uptake of antimyo-
sin antibodies.
We are grateful to Josep M. Queralto´, MD, PhD, for determinations of blood
alcoholemia and to Carme Casanovas for secretarial work.
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